

29 October 2012

'RESEARCH NEVER STOPS'

info@evotec.com | www.evotec.com

For further information,
please contact

Dr Mario Polywka
Chief Operating Officer
+44.(0)1235.44 16 76
+44.(0)1235.86 31 39 Fax
mario.polywka@evotec.com

Evotec AG
Manfred Eigen Campus
Essener Bogen 7
22419 Hamburg (Deutschland)

Evotec CEO awarded 'Turnarounder of the Year 2012'

Hamburg, Germany – 29 October 2012: Evotec AG (Frankfurt Stock Exchange: EVT, TecDAX) announced today that Dr Werner Lanthaler, Chief Executive Officer of Evotec, was awarded the prize 'Turnarounder of the Year 2012'. Due to Dr Lanthaler's temporary absence from Evotec, Dr Mario Polywka, Chief Operating Officer, accepted the award on behalf of Dr Lanthaler.

Dr Mario Polywka, Chief Operating Officer of Evotec, commented: "I am delighted to accept this award on behalf of Werner. By developing and implementing new strategies, the Management Board of Evotec was able to reduce costs significantly, increase revenue and form strategic alliances, thus paving the way for a more promising and sustainable future for our company. Our thanks go to all the employees at Evotec as this success would not have been possible without their commitment and enthusiasm."

Dr Werner Lanthaler was voted Turnarounder of the year in the category of up to 750 employees. "By implementing new strategies, Evotec reduced risks significantly and created a solid foundation for profitable growth", **said jury member Dr Nikolaus Förster, editor-in-chief of the business magazine 'impulse'**.

ABOUT THE 'TURNAROUNDER OF THE YEAR' AWARD

The 'Turnarounder of the Year' award is presented once a year by the business magazine 'impulse' and the auditing company BDO AG. It honours the performance of managers of German companies, who succeeded in improving a company's financial situation by implementing new strategies, thus turning the company's future into a positive and encouraging one. The prize is awarded in company size categories, i.e. up to 200, up to 750 and more than 750 employees. For additional information please go to www.impulse.de.

ABOUT EVOTEC AG

Evotec is a drug discovery alliance and development partnership company focused on rapidly progressing innovative product approaches with leading pharmaceutical and biotechnology companies. We operate worldwide providing the highest quality stand-alone and integrated drug discovery solutions, covering all activities from target-to-clinic. The Company has established a unique position by assembling top-class scientific experts and integrating state-of-the-art technologies as well as substantial experience and expertise in key therapeutic areas including neuroscience, pain, metabolic diseases as well as oncology and inflammation. Evotec has long-term discovery alliances with partners including Bayer, Boehringer Ingelheim, CHDI, Genentech, Janssen Medimmune/AstraZeneca, and Ono Pharmaceutical. In addition, the Company has existing development partnerships and product candidates both in clinical and pre-clinical development. These include partnerships with Boehringer Ingelheim, MedImmune and Andromeda (Teva) in the field of diabetes, and with Roche in the field of Alzheimer's disease. For additional information please go to www.evotec.com.